Acasti Pharma Inc Class A ACST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
-
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
-
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
-
Acasti to Present at the Life Sciences Investor Forum
-
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
-
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Trading Information
- Previous Close Price
- $3.06
- Day Range
- $2.91–3.17
- 52-Week Range
- $1.98–3.59
- Bid/Ask
- $3.07 / $3.14
- Market Cap
- $31.13 Mil
- Volume/Avg
- 104,979 / 18,402
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acastipharma.com
Valuation
|
Metric
|
ACST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACST
Financial Strength
|
Metric
|
ACST
|
|---|---|
Quick Ratio | 7.62 |
Current Ratio | 7.86 |
Interest Coverage | — |
Quick Ratio
ACST
Profitability
|
Metric
|
ACST
|
|---|---|
Return on Assets (Normalized) | −12.75% |
Return on Equity (Normalized) | −14.93% |
Return on Invested Capital (Normalized) | −16.25% |
Return on Assets
ACST
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Byqxfwph | Xlwx | $566.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cmzfhjppx | Kfcjyp | $119.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kxtxngt | Kpvksg | $113.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pyypyqtv | Hwtnbxz | $35.0 Bil | |||
| argenx SE ADR
ARGX
| Wmwfjwsc | Ryq | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Tqxlspstx | Fykh | $27.5 Bil | |||
| Moderna Inc
MRNA
| Hbcwpwdy | Lzf | $24.5 Bil | |||
| United Therapeutics Corp
UTHR
| Jjzvzhbhv | Dnxv | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nwtycjbt | Jlkdsz | $13.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mlwzlzfw | Wbvft | $12.4 Bil |
United States